The Latest “Buzz on the Street” Show: Featuring Pressure Biosciences Inc. (OTCQB: PBIO) Hub Platform

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences’ Ultra High Pressure HUB Platform Highly Effective in Studies to Develop Improved Methods for Food Safety.”

Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, announced that its HUB platform of unique, ultra-high pressure instruments was featured in three presentations at the world’s largest annual food science conference, the Institute of Food Technologists, which was held June 2-5, 2019 in New Orleans, LA.  The presentations reported the use of PBI’s HUB440 and HUB880 Explorer systems to advance knowledge and understanding of the effects of high pressure processing on serious food-borne pathogens in liquid food products and ground meat, and on the decontamination of such pathogens.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.

In 2016, a total of 56.9 million deaths were reported and of that number, 54% were due to the top 10 medical conditions. However, the two most common conditions were Ischaemic heart disease and stroke, which accounted for 15.2 million deaths in 2016 alone. Moreover, these two conditions have been the leading causes of global death in the past 15 years. Furthermore, other medical conditions such as chronic obstructive pulmonary disease, lower respiratory infections, Alzheimer’s, and lung cancers also accounted for millions of deaths collectively, according to the World Health Organization (WHO). The alarming number has prompted biotechnology and healthcare companies to develop new technology and medicine in order to help reduce the mortality rate. For instance, cancer deaths in the U.S. have declined by 27% in the past 25 years due to advancements in detection technology and treatment. Moreover, environmental changes have also played a large role in the decline of deaths. However, the majority of deaths in 2016 occurred in low-income countries where many people lack access to proper and adequate healthcare. While, predominantly, non-communicable diseases accounted for 71% of global deaths, ranging from 37% in low-income countries to 88% in high-income countries. And all but one of the 10 leading causes of deaths in high-income countries were non-communicable diseases. In terms of the absolute number of deaths, however, 78% of total non-communicable diseases occurred in low-and-middle-income countries, according to the WHO. Overall, the mortality rates are continuing to decline for certain medical ailments as companies continue to develop more effective treatments. And as a result, spending within the marketplace is increasing due to various investments as well as growing consumer spending. According to data compiled by Global Market Insights, the global biotechnology market is expected to surpass a value of USD 775 Billion by 2024. Additionally, the data forecasts the market to accelerate at a CAGR of 9.9%. 

Cancer is one of the large markets that many biotechnology companies predominantly target. In 2018, there were an estimated 1.73 million new cancer cases diagnosed and among the new group of diagnoses, 609,640 deaths are expected to occur, according to the American Cancer Society. Overall, the most common types of cancer diagnosed in men are prostate, lung, and colorectal while women are most commonly diagnosed with breast, lung, and colorectal cancer. And the decline in cancer mortality is largely due to steady reductions in smoking rates and advances in early detection and treatment. However, the American Cancer Society did note that not all populations are benefitting from the advancements. According to the most recent decade of available data from 2006 to 2015, the rate of new cancer cases fell by 2% per year in men and stayed the same for women. The cancer death rate from 2007 to 2014 had also declined by 1.4% per year in women and 1.8% per year in men. “This report also highlights our long-standing concerns about the underrepresentation of individuals from lower socioeconomic populations in cancer clinical trials and the access to treatment advances these trials may provide,” said Monica M. Bertagnolli, MD, FACS, FASCO, the President of the American Society of Clinical Oncology. “We must work to ensure every patient has access to cancer care that reflects their individual needs as well as the opportunity to participate in research and contribute to progress.”

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

2 Comments
  1. Raul Macias 1 month ago
    Reply

    consumers are a bit more cautious, especially with recent food poisoning regarding e.coli

  2. Kevin Hincks 1 month ago
    Reply

    I stay away from ground meat as it is more likely to be contaminated

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.